Seventeen years of statin pharmacogenetics: A systematic review

Maarten Leusink; N. Charlotte Onland-Moret; Paul I W De Bakker; Anthonius De Boer; Anke H. Maitland-Van Der Zee

doi:10.2217/pgs.15.158

Seventeen years of statin pharmacogenetics: A systematic review

Maarten Leusink, N. Charlotte Onland-Moret, Paul I W De Bakker, Anthonius De Boer, Anke H. Maitland-Van Der Zee^*

^*Corresponding author for this work

Pharmacoepidemiology and Clinical Pharmacology

University Medical Center Utrecht

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: We evaluated the evidence of pharmacogenetic associations with statins in a systematic review. Methods: Two separate outcomes were considered of interest: modification of low-density lipoprotein cholesterol (LDL-C) response and modification of risk for cardiovascular events. Results: In candidate gene studies, 141 loci were claimed to be associated with LDL-C response. Only 5% of these associations were positively replicated. In addition, six genome-wide association studies of LDL-C response identified common SNPs in APOE, LPA, SLCO1B1, SORT1 and ABCG2 at genome-wide significance. None of the investigated SNPs consistently affected the risk reduction for cardiovascular events. Conclusion: Only five genetic loci were consistently associated with LDL-C response. However, as effect sizes are modest, there is no evidence for the value of genetic testing in clinical practice.

Original language	English
Pages (from-to)	163-180
Number of pages	18
Journal	Pharmacogenomics
Volume	17
Issue number	2
DOIs	https://doi.org/10.2217/pgs.15.158
Publication status	Published - 1 Jan 2016

Keywords

candidate gene studies
genome-wide association studies
LDL cholesterol
pharmacogenetics
review
statins

Access to Document

10.2217/pgs.15.158

Cite this

@article{dc88c271c5ab40fe860492be0a623501,

title = "Seventeen years of statin pharmacogenetics: A systematic review",

abstract = "Aim: We evaluated the evidence of pharmacogenetic associations with statins in a systematic review. Methods: Two separate outcomes were considered of interest: modification of low-density lipoprotein cholesterol (LDL-C) response and modification of risk for cardiovascular events. Results: In candidate gene studies, 141 loci were claimed to be associated with LDL-C response. Only 5% of these associations were positively replicated. In addition, six genome-wide association studies of LDL-C response identified common SNPs in APOE, LPA, SLCO1B1, SORT1 and ABCG2 at genome-wide significance. None of the investigated SNPs consistently affected the risk reduction for cardiovascular events. Conclusion: Only five genetic loci were consistently associated with LDL-C response. However, as effect sizes are modest, there is no evidence for the value of genetic testing in clinical practice.",

keywords = "candidate gene studies, genome-wide association studies, LDL cholesterol, pharmacogenetics, review, statins",

author = "Maarten Leusink and Onland-Moret, {N. Charlotte} and {De Bakker}, {Paul I W} and {De Boer}, Anthonius and {Maitland-Van Der Zee}, {Anke H.}",

year = "2016",

month = jan,

day = "1",

doi = "10.2217/pgs.15.158",

language = "English",

volume = "17",

pages = "163--180",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Seventeen years of statin pharmacogenetics

T2 - A systematic review

AU - Leusink, Maarten

AU - Onland-Moret, N. Charlotte

AU - De Bakker, Paul I W

AU - De Boer, Anthonius

AU - Maitland-Van Der Zee, Anke H.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aim: We evaluated the evidence of pharmacogenetic associations with statins in a systematic review. Methods: Two separate outcomes were considered of interest: modification of low-density lipoprotein cholesterol (LDL-C) response and modification of risk for cardiovascular events. Results: In candidate gene studies, 141 loci were claimed to be associated with LDL-C response. Only 5% of these associations were positively replicated. In addition, six genome-wide association studies of LDL-C response identified common SNPs in APOE, LPA, SLCO1B1, SORT1 and ABCG2 at genome-wide significance. None of the investigated SNPs consistently affected the risk reduction for cardiovascular events. Conclusion: Only five genetic loci were consistently associated with LDL-C response. However, as effect sizes are modest, there is no evidence for the value of genetic testing in clinical practice.

AB - Aim: We evaluated the evidence of pharmacogenetic associations with statins in a systematic review. Methods: Two separate outcomes were considered of interest: modification of low-density lipoprotein cholesterol (LDL-C) response and modification of risk for cardiovascular events. Results: In candidate gene studies, 141 loci were claimed to be associated with LDL-C response. Only 5% of these associations were positively replicated. In addition, six genome-wide association studies of LDL-C response identified common SNPs in APOE, LPA, SLCO1B1, SORT1 and ABCG2 at genome-wide significance. None of the investigated SNPs consistently affected the risk reduction for cardiovascular events. Conclusion: Only five genetic loci were consistently associated with LDL-C response. However, as effect sizes are modest, there is no evidence for the value of genetic testing in clinical practice.

KW - candidate gene studies

KW - genome-wide association studies

KW - LDL cholesterol

KW - pharmacogenetics

KW - review

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84952685280&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.158

DO - 10.2217/pgs.15.158

M3 - Article

AN - SCOPUS:84952685280

SN - 1462-2416

VL - 17

SP - 163

EP - 180

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 2

ER -

Seventeen years of statin pharmacogenetics: A systematic review

Abstract

Keywords

Access to Document

Fingerprint

Cite this